New 'Living Drug' trial offers hope for patients with Hard-to-Treat leukemia
NCT ID NCT05679895
Summary
This is the first study in people testing a new type of CAR-T cell therapy called OC-1. It aims to see if this treatment is safe and can help control aggressive T-cell blood cancers (leukemia or lymphoma) that have come back or not responded to other treatments. The study will enroll about 20 patients, starting with low doses to check safety before testing higher ones.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Clínic
RECRUITINGBarcelona, Spain
Contact
-
Hospital Sant Joan de Déu
RECRUITINGBarcelona, Spain
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.